Truist Financial reaffirmed their buy rating on shares of Progyny (NASDAQ:PGNY – Free Report) in a research report released on Tuesday,Benzinga reports. Truist Financial currently has a $42.00 price target on the stock, up from their prior price target of $36.00.
Other equities research analysts have also issued reports about the company. Citigroup reiterated a “market outperform” rating on shares of Progyny in a research note on Thursday, November 5th. Barclays dropped their target price on Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, August 12th. JPMorgan Chase & Co. raised their target price on Progyny from $30.00 to $35.00 and gave the stock a “neutral” rating in a research report on Monday, November 9th. Weiss Ratings upgraded Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, Leerink Partners boosted their price target on Progyny from $37.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Eleven analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.83.
View Our Latest Stock Analysis on PGNY
Progyny Stock Performance
Shares of Progyny stock opened at $35.45 on Tuesday. The firm has a market cap of $2.61 billion, a P/E ratio of 32.52, a price-to-earnings-growth ratio of 1.66 and a beta of 0.97. The firm’s 50-day simple moving average is $29.24 and its 200-day simple moving average is $25.12. Progyny has a twelve month low of $16.10 and a twelve month high of $37.21.
Progyny (NASDAQ:PGNY – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.21. The firm had revenue of $341.25 million during the quarter, compared to analyst estimates of $340.76 million. Progyny had a net margin of 6.80% and a return on equity of 19.82%. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.15 earnings per share. On average, equities analysts forecast that Progyny will post 1.43 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO Peter Anevski sold 236,630 shares of Progyny stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $35.84, for a total transaction of $8,480,819.20. Following the completion of the transaction, the chief executive officer directly owned 710,972 shares of the company’s stock, valued at $25,481,236.48. This trade represents a 24.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin Gordon sold 11,500 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the transaction, the director owned 6,792 shares in the company, valued at approximately $189,768.48. This trade represents a 62.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 630,072 shares of company stock worth $22,363,084 over the last ninety days. Corporate insiders own 9.90% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Progyny during the second quarter valued at approximately $334,426,000. Bank of America Corp DE increased its holdings in shares of Progyny by 75.3% in the first quarter. Bank of America Corp DE now owns 1,190,996 shares of the company’s stock valued at $20,223,000 after purchasing an additional 511,609 shares in the last quarter. William Blair Investment Management LLC acquired a new stake in shares of Progyny in the second quarter valued at approximately $16,807,000. Danske Bank A S bought a new position in Progyny in the 2nd quarter worth approximately $15,243,000. Finally, Goldman Sachs Group Inc. raised its position in Progyny by 23.3% in the 3rd quarter. Goldman Sachs Group Inc. now owns 530,279 shares of the company’s stock worth $13,358,000 after purchasing an additional 100,335 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.
About Progyny
Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.
Further Reading
- Five stocks we like better than Progyny
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
